Title
Category
Credits
Event date
Cost
- PAINWeek
- 11.00 AANP
- 11.00 ACCME (All Other)
- 11.00 ACCME (MD/DO Only)
- 11.00 ACPE Pharmacy
- 11.00 ANCC
- 11.00 APA
$1,500.00
- 15.25 AANP
- 15.25 ACCME (All Other)
- 15.25 ACCME (MD/DO Only)
- 15.25 ACPE Pharmacy
- 15.25 ANCC
- 15.00 APA
$1,500.00
- PAINWeek
- 20.00 AANP
- 20.00 ACCME (All Other)
- 20.00 ACCME (MD/DO Only)
- 20.00 ACPE Pharmacy
- 20.00 ANCC
- 20.00 APA
$1,500.00
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
The coexistence of type 2 diabetes and chronic kidney disease significantly exacerbates cardiovascular and renal morbidity and mortality compared to either condition alone. Despite advances in therapy, many patients with DKD progress to kidney failure and have significant cardiovascular adverse events, and current strategies to address cardiorenal risk in these patients are inadequate.
- CMHC
- 16.25 ACPE Pharmacy
- 16.25 AMA PRA Category 1 Credit™
- 16.25 ANCC
- 16.25 CDE
- 16.25 Participation
$0.00
The 2022 CMHC Spring recorded sessions highlight the latest updates in CKD, heart failure, hypertension, type 2 diabetes, dyslipidemia, lifestyle management, obesity, and cardiovascular health, as well as translate cutting-edge medical research into practical, clinical strategies for preventing, delaying, and managing cardio-renal-metabolic disorders.
- CMHC
- 14.00 ACPE Pharmacy
- 14.00 AMA PRA Category 1 Credit™
- 14.00 ANCC
- 14.00 CDE
- 14.00 Participation
$0.00
Utilizing thought-provoking and interactive discussions, multidisciplinary experts in this masterclass cover advances in lifestyle, nutrition, genetics, and pharmacotherapy to prevent and address obesity, cardiovascular disease, hypertension, dyslipidemia, type 2 diabetes, kidney disease and more. Each section will include expert panel discussions, which will aim to provide practical approaches to patient management and interpret the latest advances to patient care.
- LivDerm
- TME
- 1.75 ACPE Pharmacy
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC
- 1.75 Participation
$0.00
Melanoma can be a life-threatening condition if left untreated. Patients with skin of color often face delays in diagnosis and treatment initiation in melanoma care. These disparities point to the need for increased awareness and education on melanoma risk and identification for clinicians and patients. Immunotherapies as mono and combination therapeutic regimens have become the gold standard in melanoma management.
- CMHC
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation
$0.00
Measuring HbA1c has been the method of choice to assess glucose control; however, it does not reflect potential glucose excursions leading to hypoglycemia or postprandial hyperglycemia, which increase the risk of long-term complications, as well as overall glycemic variability. Continuous glucose monitoring (CGM) technology can circumvent some of these issues in T2DM management by providing near real-time glucose concentrations derived from interstitial fluid; and studies with CGM have demonstrated its efficacy and safety in this setting.
- PAINWeek
- 22.00 AAFP
- 22.00 AANP
- 22.00 ACCME (All Other)
- 22.00 ACCME (MD/DO Only)
- 22.00 ACPE Pharmacy
- 22.00 ANCC
- 22.00 APA
$499.00
The enormity of CNS-related conditions poses an immense burden to public health. In 2022, there remain significant knowledge gaps among clinicians treating neurologic and psychiatric disorders. Conditions such as dementia, epilepsy, migraine, MS, and stroke require a more inclusive approach to continuing medical education.The BRAINWeek 2022 Digital All Access agenda has been crafted to address the most frequently diagnosed conditions encountered in clinical practice, with an emphasis on collaborative care among specialists and frontline practitioners.
- CMHC
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
$0.00
Aortic stenosis (AS) is a fatal disease if not treated promptly, especially in the older population. There is a need of multidisciplinary team approach for the comprehensive diagnosis, staging, risk stratification and treatment involving patient preferences, in order to optimize the management of this insidious disease. Studies have suggested that TAVR can be used as an alternative for SVAR in high risk as well as low risk patients with severe AS. Additionally, guidelines have underlined the benefits of TAVR with many terms and conditions.